Essex Woodlands Management’s Gyre Therapeutics GYRE Stock Holding History

Essex Woodlands Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,483	Closed	-$140K	–	8
2022 Q2	$140K	Hold	10,483	–	–	0.06%	9
2022 Q1	$52K	Hold	10,483	–	–	0.01%	9
2021 Q4	$72K	Hold	10,483	–	–	0.02%	10
2021 Q3	$323K	Hold	10,483	–	–	0.07%	9
2021 Q2	$340K	Hold	10,483	–	–	0.05%	9
2021 Q1	$396K	Hold	10,483	–	–	0.06%	9
2020 Q4	$496K	Hold	10,483	–	–	0.13%	8
2020 Q3	$338K	Hold	10,483	–	–	0.18%	7
2020 Q2	$462K	Hold	10,483	–	–	0.23%	7
2020 Q1	$344K	Hold	10,483	–	–	0.22%	7
2019 Q4	$535K	Hold	10,483	–	–	0.25%	8
2019 Q3	$386K	Hold	10,483	–	–	0.24%	6
2019 Q2	$579K	Hold	10,483	–	–	0.33%	6
2019 Q1	$640K	Hold	10,483	–	–	0.32%	7
2018 Q4	$625K	Hold	10,483	–	–	0.25%	7
2018 Q3	$861K	Hold	10,483	–	–	0.18%	7
2018 Q2	$933K	Hold	10,483	–	–	0.22%	7
2018 Q1	$2.11M	Hold	10,483	–	–	0.46%	8
2017 Q4	$1.09M	Hold	10,483	–	–	0.2%	8
2017 Q3	$404K	Hold	10,483	–	–	0.07%	9
2017 Q2	$372K	Hold	10,483	–	–	0.07%	9
2017 Q1	$757K	Hold	10,483	–	–	0.17%	10
2016 Q4	$778K	Hold	10,483	–	–	0.18%	10
2016 Q3	$1.45M	Hold	10,483	–	–	0.3%	10
2016 Q2	$1.82M	Hold	10,483	–	–	0.46%	10
2016 Q1	$2.02M	Hold	10,483	–	–	0.53%	9
2015 Q4	$3.78M	Hold	10,483	–	–	0.69%	9
2015 Q3	$5.66M	Buy	+10,483	New	+$16M	1.03%	7

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Essex Woodlands Management's GYRE Position: Q3 2022 in Review

Essex Woodlands Management sold out of Gyre Therapeutics (GYRE) in Q3 2022, closing a stake of 10,483 shares — an estimated $140K sold.

Essex Woodlands Management first reported a position in GYRE in Q3 2015 and held it in 28 quarters. The position peaked at $5.66M in Q3 2015. 35 funds tracked by Wall St. Rank hold GYRE as of Q3 2022.

Essex Woodlands Management reported no remaining Gyre Therapeutics position as of Q3 2022 after selling out during the quarter.
Essex Woodlands Management sold 10,483 Gyre Therapeutics shares in Q3 2022, an estimated $140K.
Essex Woodlands Management first reported a position in Gyre Therapeutics in Q3 2015 and held it in 28 quarters.
Essex Woodlands Management's Gyre Therapeutics position peaked at $5.66M in Q3 2015.
35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2022.

Based on Essex Woodlands Management's 13F filing for Q3 2022, filed 14 Nov 2022.